DiaSorin

The Simplexa® C. auris Direct kit is the first FDA authorized De Novo test designed to aid in the prevention and control of Candida auris colonization in healthcare settings. Designed with your lab in mind, this test provides uncompromising performance against all known C. auris clades with a simple, easy-to-use workflow. See how the Simplexa® C. auris Direct kit will help your lab combat a critical, multidrug-resistant fungal pathogen and support diagnostic stewardship. Meet the Simplexa® C. auris Direct kit: https://hubs.li/Q02GQgF60 #Diasorin #Cauris #candidaauris #diagnosticstewardship #HAI 

At Cape Cod Healthcare in Massachusetts, microbiology supervisor Patricia Phelan has been using a gastroenteritis panel assay that includes norovirus for the past four years to test patients and check for potential outbreaks in the hospital and the community.  Discover Phelan’s success with the VERIGENE® Enteric Pathogens Test and see how incorporating norovirus detection in GI testing supports diagnostic stewardship in our latest blog post. Read more: https://hubs.li/Q02HLGFf0 #DiagnosticStewardship #gastroenteritistesting #healthcare

How much do you know about Group B Strep? Group B Strep, or GBS, is the leading cause of meningitis and bloodstream infections in newborns, and is carried by 1 in 5 pregnant women worldwide. While GBS is harmless in most healthy adults, it can cause serious illness in newborns infected during labor and delivery.  Fortunately, reliable #GBS detection and diagnosis may support better patient outcomes through informed care. The Simplexa® GBS Direct assay provides physicians with the clinical sensitivity and specificity needed to detect GBS in antepartum women, enabling the necessary treatment to decrease the risk of GBS transmission to newborns. To learn more, visit our website: https://hubs.li/Q02HRjgd0 #strep #GBSAwareness #GBSAM24 #GBSAM2024 #starttheGBSconversation

Did you know that the LIAISON PLEX® Respiratory Flex Assay detects 19 viral and bacterial targets, and gives you the control to tailor results to patient population needs? The assay, run on the LIAISON PLEX® System, offers a simplified workflow, customizable targets, and flexible pricing using Flex™ Credits. The LIAISON PLEX RSP Flex Assay is ready to ship, getting you ahead of the curve for the upcoming respiratory season. Order your LIAISON PLEX solution by reaching out to your local sales representative today! Don’t have a sales representative, don’t worry! Fill out this form and we will send one your way: https://hubs.li/Q02FfXhJ0 #Diasorin #LIAISONPLEX

We are two weeks away from ADLM. As you are planning your schedule, remember to keep in mind our engaging in-booth (#1424) presentations: Tuesday, July 30th 10 AM “Advancing translational research using xMAP® Multiplexing Technology: Real-World Applications” with Dr. Gabriela Garcia-Soto, PhD 11 AM “Loyola University Medical Center real-world experience with the FDA-approved LIAISON® MeMed BV®” with Mark E Cichon, DO and David M Engman, MD, PhD 2 PM “Candida auris: An Emerging Threat to Public Health and the First FDA De Novo Granted Molecular Assay for Identifying At-Risk Patients” with Michelle Tabb, PhD 3 PM “Diagnostic Stewardship for Syndromic Respiratory Testing: Flexibility is the Name of the Game” with Kaisha Gonzalez, PhD Wednesday, July 31st 10 AM “Diagnostic Stewardship for Syndromic Respiratory Testing: Flexibility is the Name of the Game” with Kaisha Gonzalez, PhD 11 AM “Loyola University Medical Center real-world experience with the FDA-approved Liaison® MeMed BV®” with Mark E Cichon, DO and David M Engman, MD, PhD 2 PM “Strategies for Enlisting Clinician Advocates for a New FDA-Approved Diagnostic Test: Lessons from LIAISON® MeMed BV®” with Dr. David Engman, MD, PhD 3 PM “Candida auris: An Emerging Threat to Public Health and the First FDA De Novo Granted Molecular Assay for Identifying At-Risk Patients” with Michelle Tabb, PhD #ADLM #xMAPTechnology #diagnosticstewardship #fungalinfections #emergingdiseases #differentialtesting #lifesciences #diagnostictesting #immunodiagnostictesting

We are pleased to announce that the Simplexa® C. auris Direct kit has received FDA authorization for use on the LIAISON® MDX instrument! This step marks an important milestone in the commercial availability of a molecular assay able to detect Candida auris DNA from patients suspected of C. auris colonization in healthcare settings.  See how the Simplexa® C. auris Direct kit can support your efforts in providing optimal patient care. Read more: https://hubs.li/Q02GNJ4C0 #Diasorin #Cauris #candidaauris #diagnosticstewardship #HAI  #PressRelease

The LIAISON PLEX® System and LIAISON PLEX® Respiratory Flex Assay are ready to be shipped to your lab!  Stay ahead of the curve this respiratory season and order your LIAISON PLEX® solution today. System benefits include a simplified workflow, customizable targets, and flexible pricing using Flex™ Credits.  Please reach out to your local sales representative to discuss your lab's needs. Don’t have a sales representative, don’t worry! Fill out this form and we will send one your way: https://hubs.li/Q02Fg04t0

We’d like to thank everyone who joined us in attending the recent Labroots webinar, “Pathway to Implement Congenital CMV Screening and Future Legislation – One State's Progress” presented by Dr. Eileen Raynor. We appreciate you being a part of the #hearthedifference movement, committed to raising #CMVAwareness and providing fast, reliable congenital cytomegalovirus (cCMV) testing to help ensure healthier outcomes. Miss the live presentation? Watch the full webinar now to learn more about cCMV diagnostics and legislation: https://hubs.li/Q02DM8n20 Learn more about the Simplexa® Congenital CMV Direct kit, able to detect cCMV in babies under 21 days of age via saliva screening and urine confirmation: https://hubs.li/Q02DM8pX0 #hearthedifference #Awarenessmonth #cCMVAwareness

Attending ADLM 2024 in Chicago next month? Make a plan to stop by booth 1424 to discover how Diasorin and Luminex can support your diagnostic and multiplexing needs. We will have experts on hand to show how our trusted testing solutions can help you accelerate your diagnostic stewardship initiatives, multiple educational presentations in our booth, and see how you can achieve a competitive edge with our xMAP® Multiplexing Technology. See you in Chicago, July 30th – August 1st! Still need to register? https://hubs.li/Q02DMbJt0 #ADLM2024 #Immunodiagnostics #MolecularDiagnostics #xMAP

Diasorin is proud to create awareness of CMV along with the National CMV Foundation who are at the forefront of CMV education. Did you know that congenital CMV (cCMV) is the most common infectious cause of birth defects in the US and that one out of five babies with congenital CMV will develop long-term health problems, such as hearing loss?  Diasorin has assays that can support a physician’s diagnosis in two ways: The mother: The LIAISON® CMV assay panel (IgG, IgM) is a complete solution to aid clinicians in patient assessment of CMV. The diagnosis of Human Cytomegalovirus infection in pregnant women is of particular importance in assessing risk of fetal damage.  The baby: Diasorin’s Simplexa® Congenital CMV Direct assay is the only FDA-cleared PCR assay for the detection of CMV in both saliva swabs and urine. PCR testing in the first 3 weeks of life can aid in determining if an infant has congenital CMV. An early diagnosis allows for prompt treatment of hearing loss and provides an opportunity for early intervention for better health outcomes. Join the movement #hearthedifference with Diasorin as we do our part to ensure that babies get a chance to live healthy and happy lives and visit our website to learn more:  https://hubs.li/Q02CV8bV0 https://hubs.li/Q02CV2t30  #Diasorin #Diagnostictesting #congenitalCMV #CMV